Perspective Therapeutics doses first patient in new 1.5 mCi monotherapy cohort for lead TAT candidate

Perspective Therapeutics, Inc.

First patient dosed in Phase 1/2a trial of [212Pb]VMT01 as monotherapy at 1.5 mCi in MC1R-positive metastatic melanoma.
Cohort includes patients with brain metastases; prior imaging showed tracer uptake in brain lesions.
Combination arm with nivolumab began dosing in March 2025; Fast Track Designation from FDA granted September 2024.
Initial monotherapy results were presented at SMR October 2024; this cohort aims to refine dosing and assess brain metastasis activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.